Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is a biopharmaceutical company focused on developing treatments for metabolic dysfunction-associated steatohepatitis (MASH). On November 21, 2025, H.C. Wainwright upgraded MDGL's stock to a "Buy" rating, with the stock priced at approximately $559.75. The firm also increased its price target from $568 to $620, indicating confidence in the company's future performance.
The recent upgrade by H.C. Wainwright comes amid Madrigal's strategic moves, such as granting equity awards to new non-executive employees. These awards, part of the 2025 Inducement Plan, include 2,125 restricted stock units. They are designed to attract talent and are set to vest over four years, ensuring employee retention and alignment with company goals.
Currently, MDGL's stock is priced at $559.40, marking a 3.19% increase or $17.28 rise. The stock has fluctuated between $535 and $563.50 today, showing investor interest and market activity. Over the past year, the stock has seen a high of $577.90 and a low of $265, reflecting its volatility and growth potential.
Madrigal's market capitalization is approximately $12.41 billion, indicating its significant presence in the biopharmaceutical sector. With a trading volume of 189,851 shares on the NASDAQ, the stock shows active trading interest. The company's focus on novel therapeutics for MASH positions it well in a niche market with growth opportunities.
